Tyler Everhardt , Kelley Julian , Russell Benefield , Aaron Wilson , Nathan Wilson , Charles J. Parker , Anna Parks , Jeffrey A. Gilreath
{"title":"肥胖与非肥胖原发性急性免疫性血小板减少症患者服用地塞米松后的血小板反应","authors":"Tyler Everhardt , Kelley Julian , Russell Benefield , Aaron Wilson , Nathan Wilson , Charles J. Parker , Anna Parks , Jeffrey A. Gilreath","doi":"10.1016/j.rpth.2025.102844","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Immune thrombocytopenia (ITP) is a rare autoimmune disorder defined as a platelet count <100,000/μL, where secondary causes of thrombocytopenia have been excluded. Glucocorticoids are firstline therapy for ITP; however, data and recommendations on the impact of body weight and repeat steroid courses remain limited.</div></div><div><h3>Objectives</h3><div>We aimed to evaluate if body weight altered the response rates to dexamethasone (DEX) in the treatment of ITP.</div></div><div><h3>Methods</h3><div>We conducted a retrospective review to evaluate the effects of body weight on response to DEX in ITP. Patients were compared based on body mass index, presentation of ITP (acute or chronic), and cause of ITP (primary or secondary). Initial response, complete response, and relapse rates were among the outcomes investigated among the primary acute ITP population.</div></div><div><h3>Results</h3><div>Overall, 117 patients with ITP were identified, 49 of whom had primary acute ITP. Of these, 28 were categorized as nonobese, while 21 were obese. Nonobese patients were more likely to experience an initial platelet response to DEX than obese patients (93% vs 71%; <em>P</em> = .04), with 68% of nonobese patients also demonstrating a complete response compared with 48% of obese patients. Among patients who did not respond after 1 course of DEX, only 2 patients received another course prior to the initiation of alternative therapies. This is the second study to show that obese patients with primary acute ITP have significantly lower initial response rates and lower complete response rates to DEX compared with nonobese patients and that repeat DEX courses may be underutilized across all body mass index subgroups.</div></div><div><h3>Conclusion</h3><div>This study further highlights the need for additional data and guidance on optimal glucocorticoid dosing, especially in patients with obesity.</div></div>","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"9 3","pages":"Article 102844"},"PeriodicalIF":3.4000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Platelet response following dexamethasone in obese vs nonobese patients with primary, acute immune-mediated thrombocytopenia\",\"authors\":\"Tyler Everhardt , Kelley Julian , Russell Benefield , Aaron Wilson , Nathan Wilson , Charles J. Parker , Anna Parks , Jeffrey A. Gilreath\",\"doi\":\"10.1016/j.rpth.2025.102844\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Immune thrombocytopenia (ITP) is a rare autoimmune disorder defined as a platelet count <100,000/μL, where secondary causes of thrombocytopenia have been excluded. Glucocorticoids are firstline therapy for ITP; however, data and recommendations on the impact of body weight and repeat steroid courses remain limited.</div></div><div><h3>Objectives</h3><div>We aimed to evaluate if body weight altered the response rates to dexamethasone (DEX) in the treatment of ITP.</div></div><div><h3>Methods</h3><div>We conducted a retrospective review to evaluate the effects of body weight on response to DEX in ITP. Patients were compared based on body mass index, presentation of ITP (acute or chronic), and cause of ITP (primary or secondary). Initial response, complete response, and relapse rates were among the outcomes investigated among the primary acute ITP population.</div></div><div><h3>Results</h3><div>Overall, 117 patients with ITP were identified, 49 of whom had primary acute ITP. Of these, 28 were categorized as nonobese, while 21 were obese. Nonobese patients were more likely to experience an initial platelet response to DEX than obese patients (93% vs 71%; <em>P</em> = .04), with 68% of nonobese patients also demonstrating a complete response compared with 48% of obese patients. Among patients who did not respond after 1 course of DEX, only 2 patients received another course prior to the initiation of alternative therapies. This is the second study to show that obese patients with primary acute ITP have significantly lower initial response rates and lower complete response rates to DEX compared with nonobese patients and that repeat DEX courses may be underutilized across all body mass index subgroups.</div></div><div><h3>Conclusion</h3><div>This study further highlights the need for additional data and guidance on optimal glucocorticoid dosing, especially in patients with obesity.</div></div>\",\"PeriodicalId\":20893,\"journal\":{\"name\":\"Research and Practice in Thrombosis and Haemostasis\",\"volume\":\"9 3\",\"pages\":\"Article 102844\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Research and Practice in Thrombosis and Haemostasis\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2475037925001682\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Research and Practice in Thrombosis and Haemostasis","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2475037925001682","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景免疫性血小板减少症(ITP)是一种罕见的自身免疫性疾病,定义为血小板计数<;100,000/μL,其中已排除继发原因的血小板减少症。糖皮质激素是ITP的一线治疗方法;然而,关于体重和重复类固醇疗程的影响的数据和建议仍然有限。目的评价体重是否会改变地塞米松治疗ITP的应答率。方法回顾性评价体重对ITP患者DEX疗效的影响。根据体重指数、ITP的表现(急性或慢性)和ITP的病因(原发性或继发性)对患者进行比较。初步缓解、完全缓解和复发率是在原发性急性ITP人群中调查的结果。结果共发现ITP 117例,其中49例为原发性急性ITP。其中28人属于非肥胖,21人属于肥胖。非肥胖患者比肥胖患者更有可能出现DEX的初始血小板反应(93% vs 71%;P = .04), 68%的非肥胖患者也表现出完全缓解,而肥胖患者的这一比例为48%。在1个疗程DEX治疗后无反应的患者中,只有2例患者在开始替代治疗前接受了另一个疗程。这是第二项研究表明,与非肥胖患者相比,患有原发性急性ITP的肥胖患者对DEX的初始反应率和完全反应率明显较低,并且在所有体重指数亚组中,重复的DEX疗程可能未得到充分利用。结论:本研究进一步强调了对糖皮质激素最佳剂量的额外数据和指导的需求,特别是对肥胖患者。
Platelet response following dexamethasone in obese vs nonobese patients with primary, acute immune-mediated thrombocytopenia
Background
Immune thrombocytopenia (ITP) is a rare autoimmune disorder defined as a platelet count <100,000/μL, where secondary causes of thrombocytopenia have been excluded. Glucocorticoids are firstline therapy for ITP; however, data and recommendations on the impact of body weight and repeat steroid courses remain limited.
Objectives
We aimed to evaluate if body weight altered the response rates to dexamethasone (DEX) in the treatment of ITP.
Methods
We conducted a retrospective review to evaluate the effects of body weight on response to DEX in ITP. Patients were compared based on body mass index, presentation of ITP (acute or chronic), and cause of ITP (primary or secondary). Initial response, complete response, and relapse rates were among the outcomes investigated among the primary acute ITP population.
Results
Overall, 117 patients with ITP were identified, 49 of whom had primary acute ITP. Of these, 28 were categorized as nonobese, while 21 were obese. Nonobese patients were more likely to experience an initial platelet response to DEX than obese patients (93% vs 71%; P = .04), with 68% of nonobese patients also demonstrating a complete response compared with 48% of obese patients. Among patients who did not respond after 1 course of DEX, only 2 patients received another course prior to the initiation of alternative therapies. This is the second study to show that obese patients with primary acute ITP have significantly lower initial response rates and lower complete response rates to DEX compared with nonobese patients and that repeat DEX courses may be underutilized across all body mass index subgroups.
Conclusion
This study further highlights the need for additional data and guidance on optimal glucocorticoid dosing, especially in patients with obesity.